 A phase II trial evaluated efficacy and safety of pazopanib in 35 patients with recurrent GBM Iwamoto 2010. Two patients had a partial radiographic response by standard bidimensional measurements, whereas 9 patients 6 at the 8-week point and 3 only within the first month of treatment had decreased contrast enhancement, vasogenic edema, and mass effect but 50 reduction in tumor. The median PFS was 12 weeks and mOS was 35 weeks. Pazopanib was reasonably well tolerated with a spectrum of toxicities similar to other anti-VEGFVEGFR agents and with unexpected toxicity. 